BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BMS-790052: Additional Phase IIa data

Additional data from a double-blind Phase IIa trial in 48 treatment-naïve patients with chronic HCV genotype 1 infection showed that 42%, 92% and 83% of patients receiving once-daily 3, 10 and 60 mg BMS-790052 plus standard of care (SOC; Pegasys peginterferon alfa-2a and

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >